San Diego-based BioMed Realty Trust Inc. (NYSE: BMR) announced the appointment of Daniel M. Bradbury to its board of directors, increasing the board to eight members.
“We are pleased to welcome Dan to our board,” said Alan D. Gold, chairman and CEO of BioMed Realty. “Dan brings his extensive knowledge of the life science industry, as well as proven experience as a successful and dynamic leader, which we believe will contribute significantly to the continued sound execution of our business model.”
Bradbury is the managing member of BioBrit LLC, a life sciences consulting and investment firm. He served as CEO of Amylin Pharmaceuticals Inc., from March 2007 until its acquisition by Bristol-Myers Squibb Co. (NYSE: BMY) in August 2012.
He is currently a member of the boards of directors of Illumina Inc. (Nasdaq: ILMN), Geron Corp. (Nasdaq: GERN), Corcept Therapeutics Inc. and Castle Biosciences,Inc.
He is also on the board of trustees for the Keck Graduate Institute of the Claremont Colleges.
17190 Bernardo Center Dr.
San Diego, CA 92128